Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage II, III,or IV lung or pancreatic cancer~* Fair, poor, or very poor appetite~* Cancer associated anorexia/cachexia~* Weight loss perceived to be associated with diminished appetite~* Eastern Cooperative Oncology Group Performance score of 0, 1, 2~* Life expectancy \>3 months~* Alert and mentally competent~* Women of child-bearing potential required to use an adequate and reliable method of contraception. Post-menopausal women have to have been so for at least 1 year~* Screening laboratory values must not be clinically significant (some exceptions per protocol)~Exclusion Criteria:~* Brain, or head and neck metastases that may interfere with food consumption~* AIDS-related wasting~* Radiation therapy to the head and neck, abdomen, or pelvis within past 6 weeks, or anticipated during course of the study such that the result may interfere with food consumption~* Conditions that interfere with oral intake, or ability to swallow~* Absence of a normally functioning gut~* Mechanical obstruction of the alimentary or biliary tract, or malabsorption syndrome~* Intractable or frequent vomiting that regularly interfere with eating~* Clinically significant diarrhea~* History of recurrent thromboembolic events, a thromboembolic event in past 3 months, or long-term anticoagulation treatment for thromboembolism~* Uncontrolled diabetes mellitus, or symptomatic hypoadrenalism~* Poorly controlled hypertension, or congestive heart failure~* Pregnant/lactating females~* Use within past 30 days of an appetite stimulant~* Use within past week, or planned use during the study of parenteral nutrition or tube feedings~* Chronic use of steroids within past 3 months (intermittent short-term use allowed)~* Current use of or not willing to abstain from using illicit substances~* Allergy, hypersensitivity, or contraindication to megestrol acetate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Megestrol acetate concentrated suspension 110 mg/mL
- 2 (Type: PLACEBO_COMPARATOR): Placebo suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).